INTERVIEW: Faron Chairman Discusses Bettering Pharma's Reputation And Having No Regrets
Executive Summary
Frank Armstrong is an industry veteran with no intention of slowing down. Over his 30-year career, he has held CEO roles with five biotechnology companies and led medical science and innovation at Merck Serono, and was previously executive vice president of product development at Bayer and senior vice president of medical research and communications at Zeneca. He now chairs the Finnish pharma company Faron's board and has high hopes for its drug Traumakine.